Tampa, Florida — November 20, 2025 — Leads & Copy — CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) will release a letter to shareholders on December 2, 2025, outlining initiatives to advance the company’s strategic direction. The letter will provide updates on the S-1 filing, which aims to make CTT a full SEC reporting company, potentially unlocking access to funding and accelerating growth through patent monetization.
The shareholder letter will also detail progress in operational initiatives, including preparations for manufacturing capabilities and updates on strategic partnerships that align with CTT’s commercialization strategy. Furthermore, the release will cover the recent submission of a peer-reviewed scientific manuscript, highlighting the scientific basis of their therapeutic drug delivery technology.
CTT Pharma can be contacted at 813-606-0060.
Source: CTT Pharmaceutical Holdings, Inc.
Source: CTT Pharmaceutical Holdings, Inc.
